117 results about "Oral agents" patented technology

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

Use of a bitter melon exosome and an oral medicament prepared therefrom. The bitter melon exosome obtained from the bitter melon juice can be used for preparing a pharmaceutical formulation embedding a protein, a polypeptide, a small molecule peptide, a nucleic acid, or a small molecule compound. The compositions of the oral medicament of the present invention comprise the bitter melon exosome and an active pharmaceutical ingredient encapsulated in the bitter melon exosome. The bitter melon exosome is suitable for preparing a drug that is easily damaged by the gastrointestinal tract and is mostly administered by means of an injection route into an oral agent, and the oral agent can produce a similar therapeutic effect to that of the injection administration route by oral administration, and is convenient to use. The extraction method for the bitter melon exosome is simple and has a low cost. Moreover, the bitter melon exosome has no immunogenicity, has relatively high biocompatibility and biosafety, and has relatively strong tolerance to gastric acid and digestive tract proteolytic enzymes, and intestinal barrier permeability.

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

The invention discloses a medicinal and edible active component-small molecule peptide-nano-selenium synergistic anti-aging composition screened based on a molecular docking technology, and belongs to the technical field of functional foods and biological medicines. The composition comprises an active ingredient with homology of medicine and food, a specific molecular polypeptide Ala-Val-His-Leu-Cys-Gly-Phe-Asp-Glu-Ser-Thr-Lys-Arg-Tyr-Pro and nano-selenium, wherein the active ingredient with homology of medicine and food is screened by a molecular docking technology and is combined with senescence-related targets Nrf2 and / or SIRT1 in a high affinity manner, and the active ingredient, the specific molecular polypeptide and the nano-selenium form an active ingredient-molecular polypeptide-nano-selenium ternary complex with homology of medicine and food. The preparation method comprises the following steps: screening the medicinal and edible active ingredients meeting conditions, preparing the molecular polypeptide, mixing the medicinal and edible active ingredients to form a compound, adding the nano-selenium, stirring and combining, and freeze-drying to obtain a finished product. The composition can be prepared into an oral preparation or an external preparation, has a multi-dimensional synergistic efficient anti-aging effect of an active ingredient targeted activation pathway, direct anti-oxidation of nano-selenium and enhanced delivery of a peptide carrier, and is suitable for preparation of anti-aging drugs or functional foods.

In the various aspects and embodiments, the present disclosure provides compositions and methods for treating a human subject having long Covid or at risk of long Covid. In accordance with this disclosure, the subject receives an oral dosage form of larazotide or a derivative thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention provides an oral dosage form for, and a therapeutically effective dose for the management and / or treatment of muscular dystrophy using Sitagliptin or its pharmaceutically acceptable salt, alone or in combination with other therapeutically effective agents.

The invention belongs to the technical field of pharmaceutical preparations, and provides a novel solution type nasal administration composition of quetiapine. In the provided composition, quetiapine is completely dissolved in the composition in the form of a solution, and is administered via the nose. The quetiapine solution type nasal preparation provided by the invention has especially useful pharmacokinetic and pharmacodynamic characteristics compared with oral dosage forms on the market. Compared with other disclosed nasal nano-emulsion forms, the nasal nano-emulsion still has surprising pharmacokinetic and pharmacodynamic characteristics, shows good clinical application prospects, and is expected to meet unsatisfied clinical requirements. On the basis, the invention also provides a further improved technical scheme of high saturated dissolution concentration and a further improved technical scheme of good chemical stability for preparing the quetiapine solution type nasal preparation.

The invention relates to the technical field of biological preparations, and discloses a periodontitis improving compound preparation containing fermented lactobacillus mucus and traditional Chinese medicine extracts, and the periodontitis improving compound preparation comprises the following raw materials: an oral preparation: fermented lactobacillus mucus CQPC202403 bacterial powder; the gel comprises scutellaria baicalensis, honeysuckle, salvia miltiorrhiza, liquorice and a hydrogel matrix; the preservation number of the lactobacillus mucus CQPC202403 in the China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO.31106, and the preservation date of the lactobacillus mucus CQPC202403 is June 27, 2024. The lactobacillus mucilaginosus adopted by the invention inhibits pathogenic bacteria through competitive rejection and immunoregulation; the traditional Chinese medicine extracts such as the radix scutellariae directly destroy bacterial pellicles, and the radix scutellariae and the traditional Chinese medicine extracts cooperate with each other, so that the antibacterial effect is enhanced on the premise of not causing drug resistance.

The application discloses a traditional Chinese medicine composition for benefiting qi and moistening dryness and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The composition is composed of 10-15 parts of Huangqi, 10-15 parts of Guizhi, 10-15 parts of Baishao, 10-15 parts of Dazao, 10-12 parts of Zhigancao, 5-8 parts of Mahuang and 6-9 parts of Shanyurou. The preparation method is to decoct with water, add or not add accessories after concentration, and prepare oral dosage forms such as decoction and granules. The application is based on the theory of 'yang qi is soft and can nourish tendons' and 'qi can produce saliva', takes the core principle of warming yang, benefiting qi, transforming qi and producing saliva, restores the qi transformation function of the human body, transpires and transmits water and liquid to the oral cavity, and is specially used for treating xerostomia of the type of yang deficiency and saliva not ascending and the type of qi deficiency and not spreading. Through clinical observation on 180 cases, the total effective rate of the application reaches 90.8%, which is obviously better than that of traditional yin nourishing treatment (48.3%). The composition is warm and not dry, and is used for treating diseases caused by yang deficiency and unstable defensive qi, such as body deficiency cold, allergic rhinitis, spontaneous sweating and the like.

This invention provides methods, systems and devices for personal, secure authenticated provision of oral solid dosage forms, administered as a dosage regimen which may be altered over time. The methods and systems rely on providing a device for personal secure administration of oral solid dosage forms to a subject, where the device comprises a plurality of individually addressable oral dosage forms contained therein, wherein a first oral dosage form of the plurality contained therein differs from that of at least a second oral dosage form of the plurality, in terms of an active ingredient type, an active ingredient dosage, or a composition component of said solid oral dosage form, or any combination thereof and wherein the device provides for dispensing at least one individually addressable oral dosage form contained therein following a personal authentication protocol and wherein the device is subject to programming, which programming controls distribution of said oral dosage forms contained therein according to a first secure distribution program and wherein the device comprises a user interface and optionally at least one sensor and wherein subject response data, sensor collected data, or testing result data or any combination thereof is collected and incorporated in the programming; and_whereby the programming controls adjusting, altering or overwriting the first distribution program via a secure protocol to a second distribution program, as a function of the collected subject response data, sensor collected data, or testing result data or any combination thereof and completing an authentication protocol for dispensing the oral dosage form to the subject and dispensing the first oral dosage form within an oral cavity of the subject and following secure communication with an authorized provider,enabling adjustment, alteration or overwriting of the programming to activate the second oral dosage form distribution program in the device; and_dispensing the oral dosage forms of the second oral dosage form distribution program to the subject, whereby an oral dosage form regimen is adjusted, altered or overwritten in the device resulting in altering dispensing of the oral dosage form, by means of a secure authenticated protocol.

To provide peptides and compositions useful for treatment of gastrointestinal disorders or for colon cleansing.SOLUTION: The present invention provides compositions and methods of treating gastrointestinal disorders as well as pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. The present invention features peptides, compositions and related methods for colon cleansing treatment as well as other conditions and disorders described herein. In one embodiment, the peptides may be used to prepare subjects for colonoscopy treatment. In some embodiments, the peptides or pharmaceutically acceptable salts may be used to prepare subjects for surgery, such as bowel surgery.SELECTED DRAWING: None

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

The invention discloses an internal and external compound medicine for treating gout, which comprises an oral medicament and an external medicament, the oral medicament is prepared by taking a first pharmaceutical composition as a raw material, the external medicament is prepared by taking a second pharmaceutical composition as a raw material, and the first pharmaceutical composition is prepared from herba lycopi, rhizoma alismatis, chicory and lily; the second pharmaceutical composition is prepared from the following components in parts by weight: radix aconiti preparata, rhizoma arisaematis preparata, ligusticum wallichii, caulis spatholobi and rhizoma corydalis. According to the traditional Chinese medicine composition, internal and external treatment is achieved through the oral medicament and the external medicament, the synergistic effect of the oral medicament and the external medicament can not only achieve the purpose of treating symptoms in emergency but also take'benefit 'as attack, especially for acute gout, symptoms of patients can be rapidly improved and relieved, the pain of the patients is relieved, and both symptoms and root causes are treated through different targets and multiple ways.

The present disclosure provides oral dosage forms comprising about 8.75% w / w deuruxolitinib phosphate, about 50% to about 60% w / w microcrystalline cellulose, about 25% to about 35% w / w lactose monohydrate, about 3% to about 6% w / w polyvinylpyrrolidone, about 2% to about 4% w / w hydroxypropyl cellulose, about 0.25% to about 0.75% w / w colloidal silicon dioxide, and about 0.25% to about 0.75% w / w magnesium stearate.

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.

The invention includes improved pharmaceutical formulations of lipophilic actives, and specifically solid and semi-solid forms and oral dosage forms of such formulations that exhibit improved properties of controlled or modifiable release of actives and actives bioavailability upon dissolution in aqueous conditions at body temperature.

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

The invention relates to a pharmaceutical composition for treating or improving intestinal leakage and / or blood-brain barrier injury induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of pseudo-ginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be processed into pharmaceutically acceptable oral dosage forms such as granules, powder and the like; the pharmaceutical composition provided by the invention can improve expression of tight junction protein of vascular endothelial cells and intestinal epithelial cells, reduce the level of blood-brain barrier and intestinal barrier injury markers in blood, improve expression of tight junction protein in blood-brain barrier and intestinal barrier of sleep deprivation patients, reduce influence caused by sleep insufficiency and improve sleep deprivation effect. A new thought is provided for treating the injury problem caused by sleep insufficiency in traditional Chinese medicine.

The present application provides a device for dispensing an oral dosage form. The device comprises a cartridge comprising one or more chambers for containing an oral dosage form, wherein each of the one or more chambers comprises at least one outlet for dispensing the oral dosage form from the chamber. The device further comprises a member movable between first and second positions, wherein in the first position the member is configured to receive and contain a specific volume of an oral dosage form from one chamber of the cartridge through one outlet, wherein the member is movable to one or more intermediate positions in which the specific volume of oral dosage form is held and retained within the movable member such that the oral dosage form cannot be dispensed therefrom, and from the intermediate position to the second position in which the oral dosage form within the movable member can be dispensed therefrom.

The present invention discloses a heart-protective complex composition for improving the absorption rate of Coenzyme Q10 and a preparation method thereof, relating to the technical field of medicine and functional foods. The core active ingredients comprise Coenzyme Q10, Vitamin E, and black pepper extract within a specific mass ratio range. Pharmaceutically acceptable carriers and antioxidant synergists may also be combined to prepare various oral dosage forms. By constructing a ternary active component system with a specific ratio, the present invention achieves temporal synergy between absorption promotion and antioxidant regeneration in vivo, thereby solving the technical problems of low oral bioavailability and insufficient myocardial targeted accumulation of existing Coenzyme Q10 preparations. It significantly enhances the conversion efficiency of Coenzyme Q10 into the active form available to myocardial cells, and can be widely used in the preparation of drugs or functional foods for preventing or treating heart diseases.

Provided is an orally administered substance provided with a magnetic marker that can be detected easily by a magnetic sensor even with a small amount applied. The orally administered substance contains a composition for oral administration and a magnetic marker provided on the composition for oral administration. The magnetic marker contains a magnetic powder and a binder and has a squareness ratio of 0.40 or more.

The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic / lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

The invention relates to an infectious spleen and kidney necrosis virus recombinant adenovirus oral preparation which is characterized by comprising the following components in percentage by mass: 2-4% of bovine serum albumin, 3-7% of lactose, 1-3% of glycine, 1-3% of mannitol, 2-4% of povidone, 1-2% of talcum powder and 0.8-3% of magnesium stearate. The balance is the cultured infectious spleen and kidney necrosis virus recombinant adenovirus liquid. The infectious spleen and kidney necrosis virus recombinant adenovirus strain is used as a vaccine virus, a wrapping agent, a protective agent and the like are added and mixed, the mixture can be added into a conventional feed, vaccine oral inoculation is achieved, the immune effect is equivalent to vaccine injection inoculation, and the vaccine has the advantages of being convenient to use, saving labor cost, reducing fish body stress loss and the like. The oral preparation disclosed by the invention is good in stability, the loss rate of active substances is low within the period of validity, and the disintegration time limit accords with national regulations.

The invention discloses a traditional Chinese medicine composition for treating and preventing cardiovascular and cerebrovascular diseases and postoperative repair and recuperation based on classic famous prescription, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared by combining a prescription based on coptis and colla corii asini decoction, cassia twig decoction, cinnamomum cassia and aconitum carmichaeli decoction and poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, as well as poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction and poria cocos and In the formula, ligusticum wallichii and earthworm promote blood circulation to remove blood stasis, dredge collaterals and dissolve thrombus; hawthorn and lotus leaf are used for dissolving turbidity, lowering lipid and regulating blood fat and cholesterol; the poria cocos and the rhizoma alismatis are used for clearing damp and promoting diuresis. The whole formula has the effects of warming yang, dredging collaterals, nourishing yin and blood, promoting blood circulation to remove blood stasis, dissolving turbidity, reducing lipid, calming the heart, soothing the nerves and the like, can be used for treating cardiovascular and cerebrovascular diseases, conditioning dyslipidemia, preventing atherosclerosis and postoperative repair and nursing at the same time, is wide in application range and high in safety, can be prepared into various oral dosage forms, and has a good application prospect.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.